sclerotiorin has been researched along with Tuberculosis* in 2 studies
1 review(s) available for sclerotiorin and Tuberculosis
| Article | Year |
|---|---|
Marine natural products as potential anti-tubercular agents.
Tuberculosis has been one of the greatest global health challenges of all time. Although the current first-line anti-tuberculosis (anti-TB) medicines used in the clinic have reduced mortality, multidrug-resistance and extensively drug-resistance forms of the disease have now spread worldwide and become a global problem. Even so, few new clinically approved drugs have emerged during the past 30 years. Highly biodiverse marine organisms have received considerable attention for drug discovery in the past couple of decades, and emerging TB drug resistance has motivated interest in assessing marine natural products (MNPs) in the treatment of this disease. So far, more than 170 compounds have been isolated from marine organisms with anti-TB properties, ten of which exhibit potent activity and have the potential for further development. This review systematically surveys MNPs with anti-TB activity and illustrates the impact of these compounds on drug discovery research against tuberculosis. Topics: Animals; Antitubercular Agents; Aquatic Organisms; Biological Products; Humans; Tuberculosis | 2019 |
1 other study(ies) available for sclerotiorin and Tuberculosis
| Article | Year |
|---|---|
Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages.
As a eukaryotic-like Ser/Thr protein kinase, Mycobacterium tuberculosis virulent effector protein kinase G (PknG) mediates mycobacterial survival by regulating bacterial cell metabolic processes and preventing phagosome-lysosome fusion in host macrophages. Targeting PknG is an effective strategy for development of anti-tuberculosis (TB) drugs. In the study, we found that sclerotiorin, derived from marine fungi from the South China Sea, exhibited moderately strong inhibitory effects on recombinant PknG, with an IC Topics: Animals; Antitubercular Agents; Bacterial Load; Bacterial Proteins; Benzopyrans; Binding Sites; Dose-Response Relationship, Drug; HeLa Cells; Humans; Macrophages; MCF-7 Cells; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Mycobacterium bovis; Mycobacterium tuberculosis; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tuberculosis | 2017 |